Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cann Group ( (AU:CAN) ) has issued an update.
Cann Group Limited has announced the quotation of 567,225,103 ordinary fully paid securities on the Australian Securities Exchange (ASX) as part of a previously announced transaction. This move is expected to enhance the company’s capital structure and provide additional resources to support its operations and strategic initiatives, potentially strengthening its position in the medicinal cannabis market.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited operates in the pharmaceutical industry, focusing on the cultivation and production of medicinal cannabis products. The company is primarily involved in the development and commercialization of cannabis-based therapies and products, aiming to address various medical needs and conditions.
YTD Price Performance: -71.79%
Average Trading Volume: 4,115,458
Technical Sentiment Signal: Sell
Current Market Cap: A$8.66M
For a thorough assessment of CAN stock, go to TipRanks’ Stock Analysis page.